BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
BCI
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, July 21, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 12, 2007
View Archived Issues
Sepracor, GSK Enter $155M Deal Covering Global Lunesta Rights
Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today)
Read More
ImClone Gains On Erbitux Results; Avastin In Danger?
Read More
Enobia Gets $38M In Series B For Enzyme Replacement Trials
Read More
Nabi's 'Turnaround' Continues, Sells Biologics Unit For $185M
Read More
Aptuit Paying $64M For Evotec Chemistry Unit
Read More
Clinic Roundup
Read More
Other News To Note
Read More
